39 results about "Nucleic acid analogue" patented technology

Disclosed are a method for selective labeling of target nucleic acids on an array having nucleic acid analogue, e.g. PNA (peptide nucleic acid), probes immobilized on a support or supports, comprising adding to the array a detectable label and an agent for introducing the label into the target nucleic acids, after hybridization between the target nucleic acids and the nucleic acid analogue probes, and a method for detection of target nucleic acids using the same.

The invention discloses a drug delivery system of siRNA and a preparation. The active component of the drug delivery system is siRNA-loaded nanoparticles formed by a polymer and cationic lipid. The polymer can be a two-block copolymer or three-block copolymer of polyethylene glycol-polylactic acid or polyethylene glycols-polvlactic-co-glycolic acid. The cationic lipid can be N,N-dihydroxyethyl-N-methyl-N-2-(cholesteryloxycarbonylamino)ethyl ammonium bromide or N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride. The nanoparticles and the preparation can well transport siRNA into cells and play an effective role in the silence of target gene expression. In addition, after ligand or antibody modification, the siRNA drug delivery system can be used for better silence of the target gene on a cellular level and on an animal level. Therefore, the drug delivery system has a good prospect in drug delivery of siRNA and small nucleic acid analogues drugs for treating diseases.

The invention provides a method for enriching nucleic acids with a target sequence from a nucleic acid sample, wherein the method comprises the following steps: providing the nucleic acid sample which contains a the target nucleic acid sequence or a bait sequence which is consistent with the target nucleic acid sequence or has characteristics to the target sequence; conducting in vitro transcription by taking the bait sequence as a template so as to prepare a nucleic acid analogue, wherein the nucleic acid analogue has a binding part; fragmenting the nucleic acid sample; hybridizing the nucleic acid analogue with the nucleic acid sample, so that a nucleic acid analogue/DNA hybrid complex is formed by the nucleic acid analogue and the nucleic acid with the target sequence; and by virtue of the binding part, separating the nucleic acid analogue/DNA hybrid complex from non-specific hybrid nucleic acids, so that the nucleic acids with non-target sequences are removed. According to a preferred embodiment, the method further comprises a step of amplifying the nucleic acid analogue/DNA hybrid complex, so that the purpose of enriching the nucleic acids with the target sequence is achieved.

Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin, expression of mutated survivin or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.

Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin, expression of mutated survivin or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.

The invention provides application of a miR-325 nucleic acid analog in preparation of a sinusoid endothelial cell pathologic dysfunction treatment related product. Through recovering expression of genes of cells stabilin-2, PTPRM and YWHAQ by signal channels directly and indirectly influenced by miR-325, sinusoid endothelial cells can re-differentiate, the capacity of the sinusoid endothelial cells for regulating inflammations and resisting activation of stellate cells is promoted, and thus, vascular pathological changes can be effectively relieved.

Disclosed are: an enhancer of the activity of a nucleic acid analogue preparation; and others. Specifically disclosed is an enhancer of the activity of an nucleic acid analogue, which is characterized by comprising at least one branched amino acid selected from isoleucine, leucine and valine or a salt thereof and has an antiviral activity.

This invention provides a method for identifying one or more complexes from a library of complexes, wherein said complex or complexes are selected for their ability to perform a preselected or desired function on a target molecule or by having a pre-selected structure, each complex being designated a morphatide, said method comprising: (a) preparing a library of morphatides, comprised of: (i) a scaffolding component selected from the group consisting of nucleic acid, nucleic acid like molecule or nucleic acid analog having one or more regions of randomized sequence; (ii) one or more linker components; and (iii) one or more agent molecules or type of agent molecules, linked to the scaffolding component by one or more type of linker components; and (b)screening the library of morphatides prepared in step (a) by contacting, binding, or associating the morphatides with one or more suitable target molecules upon which a morphatide performs a preselected or desired function or to which a morphatide binds or associates through a pre-selected structure of said morphatide under conditions permitting said morphatide to perform said preselected or desired function on said target molecules or permitting said morphatide to bind or associate with said target molecules through the preselected structure; (c) separating the morphatides performing the preselected or desired function or binding or associating through the preselected structure, from the library of morphatides and target molecules; thereby identifying one or more complexes from a library of complexes, wherein said complex or complexes are selected for their ability to perform a preselected or desired function on a target molecule or by having a pre-selected structure.

The invention discloses a high-sensitivity gene mutation detection kit which comprises a PCR buffer solution, DNA polymerase without exonuclease activity, an LNA modified ARMS-like primer, a conventional primer, dNTP mixed liquid, nucleic acid dye and reference dye. The end 3' of the LNA modified ARMS-like primer is nucleic acid analogue; methylene is introduced to the sites of 2' oxygen atom and 4' carbon atom of the carbon ring of the nucleic acid analogue to form a lock structure, so that the LNA remarkably enhances the oligonucleotide identifying capability. The invention also provides a high-sensitivity gene mutation detection method adopting the kit, wherein if the result of PCR reaction has an amplification curve, the to-be-detected sample is a mutant sample; otherwise, if the result of PCR reaction does not have an amplification curve, the to-be-detected sample is a wild sample.

A method for purification of cytidinediphosphoric choline comprises the steps of contacting a cytidinediphosphoric choline solution having a pH of 0.5 to 5.0 (inclusive) and containing a nucleic acid analogue with a H-type strongly acidic cation exchange resin, and eluting cytidinediphosphoric choline adsorbed on the resin with water or an aqueous solution having an ion concentration of 0.1 mol/L or lower to thereby isolate and purify cytidinediphosphoric choline.

An object of the present invention is to provide a liposome composition containing a liposome having an excellent leakage rate of a nucleic acid analog anticancer agent, and a method for producing the same. According to the present invention, there are provided a liposome composition containing a liposome which (1) contains a nucleic acid analog anticancer agent and in which (2) a content ratio of a lysophospholipid contained in a lipid forming the liposome with respect to a total amount of phospholipids other than the lysophospholipid contained in the lipid forming the liposome is 0.01 mol % to 5 mol % and (3) a nucleic acid analog anticancer agent/lipid ratio is 2 mass % to 10 mass %, and a method for producing the same.

Oligonucleotides directed against the hypoxia-inducible factor-1α (HIP-1α) gene are provided for modulating the expression of HIF-1α. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1α. Methods of using these compounds for modulation of HIF-1α expression and for the treatment of diseases associated with the hypoxia-inducible factor-1α are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analogue, or Locked Nucleic Acid (LNA) or a combination thereof.